Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit

Propanc Biopharma (Nasdaq:PPCB) reported new preclinical and early translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma (PDAC).

Rhea-AI Summary

Propanc Biopharma (Nasdaq:PPCB) reported new preclinical and early translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma (PDAC). In orthotopic and patient-derived xenograft models, three-times-weekly intravenous PRP achieved >90% mean tumor growth inhibition versus vehicle controls (p < 0.001), markedly reduced liver and peritoneal metastases, remodeled the tumor microenvironment, and enhanced sensitivity of chemo‑resistant PDAC cells to gemcitabine/nab‑paclitaxel. According to Propanc, treated animals showed a median overall survival extension of more than 2.5‑fold versus controls, building on prior >85% inhibition data and compassionate‑use experience suggesting prolonged survival with a favorable safety profile. PRP, a fixed‑ratio combination of trypsinogen and chymotrypsinogen, has FDA Orphan Drug Designation for pancreatic cancer and is not limited to specific RAS mutations. The company is advancing GMP manufacturing, assay validation, and partnerships to support a planned Phase 1b First‑in‑Human study in approximately 40–45 patients with advanced solid tumors, with a clinical trial application expected in the coming months.

Positive

• >90% tumor growth inhibition in PDAC preclinical models (p < 0.001)
• >2.5-fold median survival extension in treated animals versus controls
• Marked reduction in metastatic burden in liver and peritoneum in models
• Enhanced chemo sensitivity of resistant PDAC cells to gemcitabine/nab-paclitaxel
• FDA Orphan Drug Designation granted for PRP in pancreatic cancer
• Planned Phase 1b trial in approximately 40–45 advanced solid tumor patients

Negative

• None.

Argus Aug 27 session 113 alerts

+109.35% close to close 25162.2x rel. volume Open Argus

Details

Market move: PPCB +109.35% in the Aug 27 session. PDAC preclinical data

+209.9% Peak in 29 min

$9.96M Market Cap

On Aug 27, the day this news came out, PPCB closed 109.35% above the previous close. Argus tracked a peak move of +209.9% during that session. Our momentum scanner recorded 113 alerts for this stock that day. Relative volume reached 25162.2x the daily average during tracking.

Data tracked by StockTitan Argus for the Aug 27 session.

Key Figures

Tumor growth inhibition: >90% mean P-value: p < 0.001 Overall survival extension: >2.5-fold +5 more

Tumor growth inhibition

>90% mean

Advanced PDAC orthotopic and PDX models versus vehicle controls

P-value

p < 0.001

Tumor growth inhibition result

Overall survival extension

>2.5-fold

Treated animals versus controls

Prior tumor growth inhibition

>85%

Previously reported PRP data

Planned study size

approximately 40–45 patients

Planned Phase 1b study in advanced solid tumors

Comparator trial size

approximately 500 patients

Daraxonrasib Phase 3 RASolute 302 trial

Median overall survival

13.2 months versus 6.6–6.7 months

Daraxonrasib versus chemotherapy in RASolute 302

Objective response rate

approximately 32% versus 11%

Daraxonrasib versus chemotherapy in RASolute 302

Historical Context

5 past events · Latest: Aug 18

5 events

1. Aug 18

   Phase 1b study update

   24h Move

   -1.7%

   Clinical trial preparation and feasibility assessment for PRP in advanced solid tumors

2. Aug 12

   PRP mechanism update

   24h Move

   +3.4%

   Differentiated PRP mechanism and planned Phase 1b study in advanced solid tumors

3. Aug 06

   PDAC preclinical data

   24h Move

   +15.3%

   Tumor growth inhibition, metastasis reduction, and survival extension in PDAC models

4. Aug 05

   Share repurchase

   24h Move

   +15.7%

   Completion of the first $500,000 tranche of the $5.0 million repurchase program

5. Jul 21

   Research publication

   24h Move

   +0.0%

   Peer-reviewed evaluation of recombinant trypsinogen and chymotrypsinogen

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

pdac, patient-derived xenograft, epithelial-mesenchymal transition, pharmacokinetics, +2 more

6 terms

pdac medical

"data for PRP in pancreatic ductal adenocarcinoma (PDAC)"

PDAC stands for pancreatic ductal adenocarcinoma, the most common and aggressive form of pancreatic cancer that starts in the pancreas’s duct cells. It matters to investors because PDAC represents a large unmet medical need with high patient mortality, driving intense drug development, clinical trial activity and potential regulatory milestones—like a critical, hard-to-fix engine part whose failure creates urgent demand for effective solutions, affecting a company’s valuation and risk profile.

patient-derived xenograft medical

"orthotopic and patient-derived xenograft (PDX) models"

A patient-derived xenograft (PDX) is a laboratory model created by implanting a tumor or diseased tissue taken directly from a human patient into an animal host that can support its growth. Because PDX models tend to mirror how a human tumor behaves and responds to treatments better than simple cell cultures, investors view their use as a stronger signal that preclinical drug results may translate to patients, lowering development risk much like a full-scale dress rehearsal raises confidence before opening night.

epithelial-mesenchymal transition medical

"suppression of epithelial-mesenchymal transition (EMT) markers"

A biological process in which normally stationary, tightly connected cells change into a more flexible, mobile state that lets them move and invade other tissues, like bricks in a wall turning into travelers. For investors, it matters because this behavior can drive disease aggressiveness, treatment resistance and influence which drug targets and diagnostic tests are valuable, affecting clinical trial success, commercial prospects and company valuations.

pharmacokinetics medical

"progressing GMP manufacturing, pharmacokinetics assay validation"

Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.

gmp regulatory

"progressing GMP manufacturing"

Good Manufacturing Practice (GMP) is a set of regulatory standards and procedures that ensure products—especially medicines, medical devices, and related goods—are consistently made to meet safety, quality, and purity requirements. For investors, GMP compliance is like a factory’s hygiene and checklist system: it reduces the risk of product recalls, regulatory fines, and production stoppages, supports market access, and signals more reliable, lower-risk operations that can protect revenue and reputation.

orphan drug designation regulatory

"holds FDA Orphan Drug Designation for pancreatic cancer"

Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Differentiated Profile versus RAS-Targeted Approaches Including Revolution Medicines’ Daraxonrasib

MELBOURNE, Australia, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced compelling new preclinical and early translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma (PDAC).

In orthotopic and patient-derived xenograft (PDX) models of advanced PDAC, three-times-weekly intravenous PRP achieved:

• Greater than 90%, mean, tumor growth inhibition versus vehicle controls (p < 0.001).
• Marked reduction in metastatic burden in the liver and peritoneum.
• Significant remodeling of the tumor microenvironment, including decreased cancer-associated fibroblast activity, reduced fibrosis, and suppression of epithelial-mesenchymal transition (EMT) markers.
• Enhanced sensitivity of chemo-resistant PDAC cells to standard-of-care gemcitabine/nab-paclitaxel, supporting lower chemotherapy doses with improved efficacy.
• Median overall survival extension of more than 2.5-fold in treated animals compared with controls.
  
  

These results were built on previously reported >85% tumor growth inhibition data and peer-reviewed findings on PRP’s effects on PDAC fibroblasts. Limited prior compassionate-use experience with related proenzyme formulations has shown signals of prolonged survival in advanced solid-tumor patients with a favorable safety profile and no severe treatment-related adverse events.

Comparison to Revolution Medicines Clinical Data

Revolution Medicines’ multi-selective RAS(ON) inhibitor daraxonrasib recently delivered practice-changing Phase 3 results (RASolute 302) in previously treated metastatic PDAC. In that trial of approximately 500 patients, daraxonrasib achieved median overall survival of 13.2 months versus 6.6–6.7 months with chemotherapy (hazard ratio 0.40; ~60% reduction in risk of death), median progression-free survival of 7.2–7.3 months versus 3.5–3.6 months, and objective response rates of approximately 32% versus 11%.

While these clinical outcomes represent a major advance for RAS-mutant disease (present in ~90% of PDAC cases), PRP operates through a fundamentally different mechanism. PRP is a proprietary fixed-ratio combination of the two pancreatic proenzymes, trypsinogen and chymotrypsinogen. It promotes differentiation of malignant cells toward a more normal phenotype, reverses EMT, targets cancer stem cells, suppresses metastasis and angiogenesis, and remodels the supportive tumor microenvironment—without relying on cytotoxic pathway inhibition.

Propanc believes this non-cytotoxic, differentiation-based approach addresses key drivers of resistance, recurrence, and dissemination that persist even after RAS pathway blockade. PRP holds FDA Orphan Drug Designation for pancreatic cancer and is not limited to specific RAS mutations, supporting potential broad applicability across solid tumors and possible use in combination or sequential settings with RAS inhibitors or standard chemotherapy.

“Pancreatic cancer remains one of oncology’s greatest challenges, with five-year survival rates still near 13% and limited durable options for patients with metastatic disease,” said James Nathanielsz, Chief Executive Officer of Propanc. “The recent clinical progress with RAS(ON) inhibitors such as daraxonrasib is tremendously exciting. Our new data reinforce PRP’s differentiated mechanism—targeting cancer stem cells, disrupting the fibrotic microenvironment, and potentially overcoming resistance—and give us strong conviction as we advance into the clinic. We are accelerating our Phase 1b First-in-Human study in advanced solid tumors, with pancreatic cancer as a key focus indication.”

The Company is progressing GMP manufacturing, pharmacokinetics assay validation, and clinical partnerships in support of a planned Phase 1b study in approximately 40 – 45 patients with advanced solid tumors. A clinical trial application is expected in the coming months.

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.

More information: www.propanc.com

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

Company:
Propanc Biopharma, Inc.
James Nathanielsz

+61-3-9882-0780

info@propanc.com

Investor Contact:

irteam@propanc.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What new pancreatic cancer data did Propanc Biopharma (NASDAQ:PPCB) announce for PRP on August 27, 2026?

Propanc Biopharma reported strong preclinical PRP results in pancreatic ductal adenocarcinoma, including over 90% mean tumor growth inhibition and more than 2.5-fold median survival extension in treated animals. According to Propanc, these findings also showed reduced metastases and major tumor microenvironment remodeling in advanced PDAC models.

How much tumor growth inhibition and survival benefit did PRP show in Propanc Biopharma (PPCB) PDAC models?

PRP achieved greater than 90% mean tumor growth inhibition versus controls and extended median overall survival by more than 2.5-fold in PDAC animal models. According to Propanc, these effects were observed in orthotopic and patient-derived xenograft models of advanced pancreatic ductal adenocarcinoma.

How does Propanc Biopharma’s PRP differ from RAS inhibitors like daraxonrasib for pancreatic cancer (PPCB)?

PRP uses a non-cytotoxic, differentiation-based mechanism, while daraxonrasib is a multi-selective RAS(ON) inhibitor. According to Propanc, PRP’s proenzyme combination targets cancer stem cells, reverses epithelial-mesenchymal transition, remodels the fibrotic microenvironment, and is not limited to specific RAS mutations in solid tumors.

What are the next clinical development steps for PRP in Propanc Biopharma’s (NASDAQ:PPCB) program?

Propanc plans a Phase 1b First-in-Human study of PRP in approximately 40–45 patients with advanced solid tumors. According to Propanc, GMP manufacturing, pharmacokinetics assay validation, and clinical partnerships are progressing, with a clinical trial application expected in the coming months.

Does PRP have FDA Orphan Drug Designation, and what does it cover for Propanc Biopharma (PPCB)?

Yes, PRP holds FDA Orphan Drug Designation specifically for pancreatic cancer. According to Propanc, PRP’s mechanism is not restricted to particular RAS mutations, suggesting potential applicability across solid tumors and possible combination or sequential use with RAS inhibitors or standard chemotherapy.

What preclinical effects did PRP show on the tumor microenvironment in Propanc Biopharma (PPCB) studies?

PRP demonstrated significant tumor microenvironment remodeling, including decreased cancer-associated fibroblast activity, reduced fibrosis, and suppression of epithelial-mesenchymal transition markers. According to Propanc, these changes were accompanied by reduced metastatic burden and increased sensitivity to standard gemcitabine/nab-paclitaxel chemotherapy in PDAC models.